Novartis Health Press Releases — RSS Feed & Live Monitoring
PPN World indexes Novartis press releases and archives each one it distributes. This wire has been quiet since July 21, 2026 — its 21 indexed releases remain searchable, and an alert will tell you the moment it publishes again.
Novartis RSS feed URL
https://hpampthnhbmgpdxezfop.supabase.co/functions/v1/scrape-config?config=novartis-com-media-releasesAbout this feed
Novartis is one of the 1200+ press-release feeds PPN World monitors around the clock — an English-language wire focused on Health, filed under Switzerland in our country index. Every release is deduplicated, geotagged, and enriched with an AI summary, and you can attach saved-search alerts to any keyword it publishes. The most recent release in our index was published on July 21, 2026; the wire has been quiet since.
How to follow Novartis press releases
- Copy the Novartis RSS feed URL shown above.
- Paste it into any RSS reader (Feedly, Inoreader, NetNewsWire…) to get the raw feed.
- Or track Novartis in PPN World to add deduplication, saved-search alerts, and AI summaries across all 1200+ wires.
Novartis press releases — archive
- Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed9 d ago
Ad hoc announcement pursuant to Art. 53 LRSecond quarterNet sales grew +1% (cc1, +3% USD), with core operating income1 flat (cc and USD)Sales growth driven by priority brands including Kisqali (+43%…
- Novartis verzeichnete im zweiten Quartal Umsatzsteigerungen und baute die Pipeline weiter aus; Prognose für das Geschäftsjahr bekräftigt9 d ago
Ad-hoc-Mitteilung gemäss Art. 53 KRZweites QuartalDer Nettoumsatz stieg um +1% (kWk1, +3% USD), das operative Kernergebnis1 blieb unverändert (kWk und USD)Das Umsatzwachstum beruhte auf den…
- Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN13 d ago
Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 Clinically meaningful improvements of protein in urine observed as early as two weeks,…
- Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients24 d ago
Adds potential first-in-class, N-myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) payload platform, designed to address resistance to current payloads Strengthens the Novartis…
- Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)28 d ago
First gene replacement therapy in the EU for broad population with SMA, including children two years and older, teens and adults Fixed, one-time dose designed to replace the faulty SMN1 gene,…
- Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)48 d ago
Rhapsido demonstrated statistically significant and clinically meaningful symptom control in twice as many patients vs placebo1, with favorable safety profile and no observed liver safety…
- Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint49 d ago
Ad hoc announcement pursuant to Art. 53 LR FORTITUDE study met primary and key secondary endpoints of reduction in KHDC1L and creatine kinase levels, with safety profile consistent with previous…
- Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 202652 d ago
Results from Rhapsido (remibrutinib) pivotal Phase III RemIND trial, the largest study in chronic inducible urticaria, to be highlighted in late-breaker oral presentationNew Phase IIIb REMIXED…
- Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years56 d ago
Phase III ALIGN study results showed reduced rate of kidney function decline by ~34% with Vanrafia vs placebo, based on supportive eGFR slope analysis1Vanrafia reduced protein in urine by 38.3% vs…
- Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients57 d ago
Clinically meaningful, statistically significant efficacy achieved in primary and all secondary endpoints, including reduced steroid use; safety consistent with established Cosentyx profile1,…
- Scemblix® continued to show superior efficacy and favorable safety and tolerability profile at week 144 in newly diagnosed CML59 d ago
Growing improvement in major molecular response (MMR) rates demonstrated with Scemblix vs. all standard-of-care TKIs including imatinib and second generation (2G) TKIs1 Clinically relevant 15.2%…
- Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases59 d ago
New Cosentyx® (secukinumab) data from REPLENISH, largest ever global Phase III trial in polymyalgia rheumatica, to be highlighted in oral sessionNew ianalumab interim results from Sjögren’s Phase III…
The newest releases on this wire stream live for PPN World members.
Frequently asked questions
How do I follow Novartis press releases in real time?+
Is there an RSS feed for Novartis?+
What is the Novartis RSS feed URL?+
What kind of press releases does Novartis publish?+
Related feeds
- Presseportal (Schweiz)
- Presseportal Schweiz (PPS)
- Swiss-Press.com (HELP Media)
- République et canton de Genève — Communiqués et publications
- Stadt Zürich — Medienmitteilungen
- Kanton Bern Medienmitteilungen
- Swiss National Bank
- EPFL News
- Kanton Graubünden — Medienmitteilungen Standeskanzlei
- Ville de Genève — Actualités